Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of skildklierkanker.
Eisai het gesê dat Lenvima die nuwe standaard sal word vir kliniese behandeling van onopereerbare skildklierkanker. Die bedryf is baie optimisties oor Lenvima, en daar word verwag dat die middel 'n nuwe kontantkoei vir Eisai sal word, met jaarlikse verkope wat 'n hoogtepunt van meer as $1 miljard bereik.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumor volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Tans, hoewel die meeste tipes skildklierkanker behandel kan word, is daar min opsies vir behandeling sodra dit erger word. Differensiële skildklierkanker (DTC) is die mees algemene kwaadaardige skildkliergewas, en die voorkoms daarvan het die afgelope paar jaar geleidelik toegeneem.
Lenvatinib is 'n orale multi-reseptor tirosienkinase (RTK) inhibeerder met 'n nuwe bindingsmodus. Benewens die inhibering van ander RTK's betrokke by tumorproliferasie en onkogene seinweë, kan dit ook selektief vaskulêre endoteelgroeifaktor (VEGF) reseptorkinase-aktiwiteit inhibeer.
